Skinvisible (SKVI) Short-term Investments (2021)
Skinvisible's (SKVI) quarterly Short-term Investments came in at $111224.0 in Q3 2021, down 41.67% quarter-over-quarter from $190669.0 in Q2 2021.
Powered by 
Analysis
Skinvisible (SKVI) Short-term Investments (2021) Analysis & Trends
Skinvisible has disclosed Short-term Investments across 1 years of filings, most recently posting $111224.0 for Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.22 Bn | 626.46 Bn | 17.26 Bn |
| 2 | AbbVie | 440.28 Bn | 433.71 Bn | 12.70 Bn |
| 3 | Merck | 364.30 Bn | 357.16 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.44 Bn | 260.75 Bn | 11.24 Bn |
| 5 | Pfizer | 158.60 Bn | 146.90 Bn | 10.94 Bn |
| 6 | Sanofi | 52.56 Bn | 45.18 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.31 Bn | 44.31 Bn | - |
| 8 | Incyte | 24.98 Bn | 20.45 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.16 Bn | 18.49 Bn | 683.80 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 |